ZBTB21

ZBTB21 (ZNF295) is a BTB/POZ–zinc-finger transcription factor that functions predominantly as a sequence-specific transcriptional repressor controlling neural gene programs, chromatin architecture, and immune gene expression (PMID:15629158, PMID:38959316, PMID:37264934). Its repressive activity is housed in two separable domains, the BTB/POZ domain and a central region between the BTB/POZ and zinc-finger domains, and the protein self-associates as homodimers and heterodimerizes with the related POK factor ZFP161; alternatively spliced long and short isoforms differ in zinc-finger content (PMID:15629158). ZBTB21 binds canonical cAMP-response element (CRE) DNA in direct competition with CREB, thereby repressing CRE-dependent transcription and negatively regulating synaptic plasticity, learning and memory; normalization of Zbtb21 copy number rescues cognitive and synaptic deficits in a Down syndrome mouse model (PMID:38959316). Beyond promoter-level repression, ZBTB21 associates with cohesin on chromatin and promotes cohesin occupancy and 3D chromatin interactions, acting redundantly with ZBTB7B (PMID:37264934). In immune control it epigenetically silences GSDMD-dependent pyroptosis by limiting STAT1-driven chromatin accessibility via H3K27ac and represses MHC-I antigen presentation by attenuating IRF1, such that its loss unleashes pyroptosis and CD8+ T-cell-mediated antitumor responses (PMID:41655210). Its transcriptional output is tuned by SUMOylation at conserved lysines (K419, K845), which switches ZBTB21 between activator and repressor states without altering localization or stability (PMID:38666079), and during early vertebrate development it cooperates with ZBTB14 to pattern the anterior-posterior neural axis (PMID:36166855).

1. 2005 Medium

   Establishing whether ZNF295/ZBTB21 was a regulator at all, this work defined it as a multidomain transcriptional repressor with two independent repression modules and identified its dimerization behavior.

   Evidence Promoter-reporter transcription assays and co-immunoprecipitation of isoforms in cultured cells

   PMID:15629158

   Open questions at the time

   • No endogenous target genes or DNA-binding sites identified
   • Functional difference between long and short isoforms not resolved
   • Physiological context of ZFP161 partnership untested
2. 2022 Medium

   To place ZBTB21 in a developmental program, loss- and gain-of-function in Xenopus showed it patterns the anterior-posterior neural axis in cooperation with ZBTB14.

   Evidence Morpholino knockdown and overexpression in Xenopus embryos and ectodermal explants with neural marker analysis

   PMID:36166855

   Open questions at the time

   • Direct target genes mediating AP patterning not defined
   • Molecular basis of ZBTB14 cooperation unknown
   • Relevance to mammalian neural development untested
3. 2023 High

   Moving from promoter-level repression to genome architecture, ZBTB21 was shown to bind cohesin and support its chromatin occupancy and 3D genome interactions, redundantly with ZBTB7B.

   Evidence Cohesin interactome MS, degron-based acute degradation, cohesin ChIP-seq time-series, and BAT Hi-C

   PMID:37264934

   Open questions at the time

   • Direct vs. indirect nature of the ZBTB21–cohesin interaction not fully resolved
   • Which loci depend on ZBTB21 for cohesin loading unclear
   • Mechanism of redundancy with ZBTB7B undefined
4. 2024 High

   Defining a specific DNA-binding mode, ZBTB21 was shown to occupy CRE elements in competition with CREB to repress cAMP-dependent transcription and constrain synaptic plasticity, with in vivo rescue linking it to Down syndrome cognitive phenotypes.

   Evidence ChIP, competitive binding assays with CREB, copy-number genetic rescue in DS mice, behavioral and electrophysiological readouts

   PMID:38959316

   Open questions at the time

   • Genome-wide CRE target repertoire not catalogued
   • Whether competition with CREB occurs at endogenous loci genome-wide unproven
   • Mechanistic link between CRE repression and synaptic deficits incomplete
5. 2024 Medium

   Addressing how ZBTB21 switches between activation and repression, SUMOylation at conserved lysines K419/K845 was shown to modulate its transcriptional output without altering localization or stability.

   Evidence Site-directed mutagenesis of SUMO-acceptor lysines, Western blot, Co-IP, luciferase reporters, immunofluorescence in zebrafish system

   PMID:38666079

   Open questions at the time

   • SUMO E3 ligase and promoter context determining the switch unidentified
   • Mechanistic basis for differential promoter outcomes unresolved
   • Conservation of the SUMO switch in mammalian ZBTB21 untested
6. 2026 Medium

   Extending ZBTB21 into immune regulation, its ablation was shown to unleash GSDMD-dependent pyroptosis and MHC-I antigen presentation via H3K27ac/STAT1 and IRF1 control, defining it as a targetable immune brake in tumors.

   Evidence Genetic KO, chromatin accessibility and H3K27ac ChIP, IRF1 transactivation reporters, tumor models, CD8+ T-cell assays, small-molecule inhibition (dobutamine)

   PMID:41655210

   Open questions at the time

   • Not independently replicated
   • Direct binding of ZBTB21 at GSDMD and MHC-I regulatory loci vs. indirect effects not fully separated
   • Specificity and clinical relevance of dobutamine inhibition unestablished

• A unified picture of how ZBTB21's DNA-binding, cohesin association, SUMO-dependent activator/repressor switching, and tissue-specific target selection are integrated remains unresolved.
• No genome-wide ZBTB21 binding map linking its CRE, cohesin, and immune functions
• No structural model of the DNA-binding domain despite reported pharmacological targeting
• How a single factor reconciles repressor and activator roles across tissues is undefined